Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read an analysis of MRNA stock now.

When short-sellers (bears) bet heavily against companies on the S&P 500 (IVV), investors should not ignore them. Enphase ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

But its financial fortunes have reversed since then due to declining demand for COVID-19 shots and slow uptake for an RSV vaccine it’s also brought to market. Moderna has revised its revenue guidance ...

Moderna reported negligible mRESVIA (RSV vaccine) sales in the second quarter of 2025. Moderna’s RSV vaccine for adults aged 60 years and older has been approved in approximately 40 countries.

Multiple Massachusetts-based vaccine companies, including Moderna, are affected by U.S. Health and Human Services Secretary ...

The American Academy of Pediatrics is splitting from the federal government in its recommendations on which children should ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.

Despite questions coming from federal changes, Colorado’s chief medical officer says he thinks “there will be enough vaccines ...